Alnylam Pharmaceuticals (ALNY) reported Q1 non-GAAP net loss Thursday of $0.01 per diluted share, narrower than the $0.16 net loss a year earlier.
Analysts polled by FactSet expected a loss of $0.38.
Revenue for the quarter ended March 31 was $594.2 million, up from $494.3 million a year earlier.
Analysts surveyed by FactSet expected $588.4 million.
The company reiterated its full-year 2025 guidance of $2.05 billion to $2.25 billion for total net product revenue, and $650 million to $750 million for net revenue from collaborations and royalties.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.